PE20050571A1 - Tienoimidazoles sustituidos y procedimiento para su preparacion - Google Patents

Tienoimidazoles sustituidos y procedimiento para su preparacion

Info

Publication number
PE20050571A1
PE20050571A1 PE2004000847A PE2004000847A PE20050571A1 PE 20050571 A1 PE20050571 A1 PE 20050571A1 PE 2004000847 A PE2004000847 A PE 2004000847A PE 2004000847 A PE2004000847 A PE 2004000847A PE 20050571 A1 PE20050571 A1 PE 20050571A1
Authority
PE
Peru
Prior art keywords
procedure
tienoimidazoles
substitute
preparation
thenylamine
Prior art date
Application number
PE2004000847A
Other languages
English (en)
Inventor
Hans-Joechen Lang
Uwe Heinelt
Klaus Wirth
Thomas Licher
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20050571A1 publication Critical patent/PE20050571A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I O II, DONDE R1 ES FENILO O 3-TIENILO SUSTITUIDOS CON LOS RADICALES R5 Y R6 EN LAS POSICIONES 2 Y 6; R5 Y R6 SON CADA UNO H, CH3, CICLOALQUILO C3-C5, VINILO, ENTRE OTROS; R2 Y R3 SON CADA UNO H, F, Cl, CN, OH, ENTRE OTROS; R4 ES H, METILO, ETILO, CICLOPROPILO, CICLOPROPILMETILO,CH2-CF3. SON COMPUESTOS PREFERIDOS: 2-(4-METIL-3-TIENILAMINO)-1H-TIENO[3,4-d]IMIDAZOL; 2-(2,6-DICLOROFENILAMINO)-1H-TIENO[3,4-d]IMIDAZOL; 2-(2,4-DICLORO-3-TIENILAMINO)-1H-TIENO[3,4-d]IMIDAZOL.SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO. DICHOS COMPUESTOS SON INHIBIDORES DE INTERCAMBIO DE SODIO/PROTONES (NHE) UTILES EN EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS, TRSTORNOS AGUDOS Y CRONICOS DE LOS RINONES E INTESTINOS, TRATAMIENTO O PROFILAXIS DE TRASTORNOS DEL SNC, ENTRE OTROS
PE2004000847A 2003-09-08 2004-09-02 Tienoimidazoles sustituidos y procedimiento para su preparacion PE20050571A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10341240A DE10341240A1 (de) 2003-09-08 2003-09-08 Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
PE20050571A1 true PE20050571A1 (es) 2005-12-02

Family

ID=34258478

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000847A PE20050571A1 (es) 2003-09-08 2004-09-02 Tienoimidazoles sustituidos y procedimiento para su preparacion

Country Status (23)

Country Link
US (1) US7179830B2 (es)
EP (1) EP1664058B1 (es)
JP (1) JP2007505035A (es)
KR (1) KR20060069489A (es)
CN (1) CN1845926A (es)
AR (1) AR045600A1 (es)
AT (1) ATE378343T1 (es)
AU (1) AU2004272225A1 (es)
BR (1) BRPI0414191A (es)
CA (1) CA2537695A1 (es)
DE (2) DE10341240A1 (es)
GT (1) GT200400148A (es)
IL (1) IL173918A0 (es)
MA (1) MA28026A1 (es)
MX (1) MXPA06001830A (es)
NO (1) NO20061559L (es)
PA (1) PA8611401A1 (es)
PE (1) PE20050571A1 (es)
RU (1) RU2006111467A (es)
SV (1) SV2005001872A (es)
TW (1) TW200521130A (es)
WO (1) WO2005026173A1 (es)
ZA (1) ZA200601001B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2804574T3 (es) 2008-05-09 2021-02-08 Merck Patent Gmbh Composición farmacéutica para tratar enfermedades asociadas con la resistencia a la insulina y la disfunción de células beta
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
CN102964354B (zh) * 2012-11-16 2014-08-13 江苏先声药业有限公司 一类噻吩并咪唑衍生物及其应用
PL3131890T3 (pl) * 2014-04-17 2019-12-31 Institut Pasteur Korea Związki do leczenia zakażeń wirusowych
LT3173408T (lt) 2014-07-25 2018-12-27 Taisho Pharmaceutical Co., Ltd. Fenilo tetrahidroizochinolino junginys, turintis heteroarilo pakaitų

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754935A (fr) 1969-08-13 1971-02-17 Hoechst Ag 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation
AU636066B2 (en) * 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
DE4034728A1 (de) * 1990-10-30 1992-05-07 Schering Ag Neue thienoimidazolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE19633966A1 (de) 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19945302A1 (de) 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
DE10015248A1 (de) 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
DE10060292A1 (de) 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament

Also Published As

Publication number Publication date
ATE378343T1 (de) 2007-11-15
PA8611401A1 (es) 2005-03-28
RU2006111467A (ru) 2006-08-10
CN1845926A (zh) 2006-10-11
AR045600A1 (es) 2005-11-02
ZA200601001B (en) 2007-03-28
WO2005026173A1 (de) 2005-03-24
GT200400148A (es) 2007-03-22
IL173918A0 (en) 2006-07-05
DE502004005522D1 (de) 2007-12-27
EP1664058A1 (de) 2006-06-07
US7179830B2 (en) 2007-02-20
SV2005001872A (es) 2005-03-09
TW200521130A (en) 2005-07-01
KR20060069489A (ko) 2006-06-21
NO20061559L (no) 2006-04-06
EP1664058B1 (de) 2007-11-14
BRPI0414191A (pt) 2006-10-31
MXPA06001830A (es) 2006-05-31
CA2537695A1 (en) 2005-03-24
DE10341240A1 (de) 2005-04-07
AU2004272225A1 (en) 2005-03-24
JP2007505035A (ja) 2007-03-08
US20050075385A1 (en) 2005-04-07
MA28026A1 (fr) 2006-07-03

Similar Documents

Publication Publication Date Title
HRP20031098B1 (en) Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
SE0302487D0 (sv) Novel compounds
SE0302486D0 (sv) Novel compounds
DK1682138T3 (da) Heterocykliske inhibitorer af MEK
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
NO20044995L (no) Heterosykliske forbindelser
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
SE0202463D0 (sv) Novel compounds
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
HK1089163A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
SE0302323D0 (sv) Novel compounds
WO2007039781A3 (en) 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors
AR047466A1 (es) Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles.
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
DE602004012400D1 (de) N-ä(piperazinyl)hetarylüarylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor
PE20050571A1 (es) Tienoimidazoles sustituidos y procedimiento para su preparacion
EA200600570A1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht
AR048326A1 (es) Derivados de prolinilo
DK1648904T3 (da) N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander

Legal Events

Date Code Title Description
FC Refusal